Author/Treatment

Patients Total No.

Prior treatment

Efficacy response

(%)

Survival

PFS

OS (%)

Radiation therapy (%)

Chemotherapy (%)

CR

PR

Median (months)

6 months (%)

Median (months)

6 months

1 year

2 years

10 years

KREISL et al., 2009 BVZ; First stage alone, Second stage with irinotecan [29]

48

All

All

2

33

4

29

7.7

57

FRIEDMAN et al., 2009 Randomized trial assessing BVZ alone with BVZ and irinotecan [30]

85^*

All

All

1.2

27

4.2

42.6

9.2

CHAMBERLAIN et al., 2010 Retrospective analysis of BVZ alone [31]

50

All

All

0

58

42

8.5

BURKHARDT et al., 2012 Phase I trial of intra-arterial BVZ after blood brain barrier disruption [32]

14

All

All

0

57

10

8.8

RAIZER et al., 2010 Erlotinib, Phase II [33]

38

All

All

0

0

2

3

6

IWAMOTO et al., 2010 Pazopanib, Phase II [34]

35

All

All

0

5.7

3

3

8

GALANIS et al., 2009 Vorinostat, Phase II study [35]

66

All

All

0

3

15.2

5.7

GALANIS et al., 2005 Temsirolimus, Phase II study [36]

65

All

45

0

0

7.8

5.2

SATHORNSUMETEE et al., 2010 Phase II analysis of BVZ and erlotinib [37]

25

All

All

4

44

4

26

10.5

REARDON et al., 2010 Erlotinib and sirolimus, Phase II study [38]

32

All

All

0

0

1.6

3.1

7.9

LU-EMERSON et al., 2011 Dasatinib and BVZ retrospective study [39]

14

All

All

0

0

1

0

2.5

REARDON et al., 2011 Sorafenib and TMZPhase II study [40]

32

All

All

0

3

1.5

6.4

10.3

FRIDAY et al., 2012 Vorinostat and bortezomib, Phase II study [41]

37

All

All

0

0

0

3.2

S. R. Burzynski et al., 2014 ANP, Phase II study RGBM

30

87

67

6.7

6.7

2.1

16.7

8.3

55.5

34.7

3.5

3.5

S. R. Burzynski et al., 2014 ERGBM

24

88

75

8.3

8.3

2.4

20.8

11.2

65.5

39.3

4.4

4.4